Program
camrelizumab
Also written as “SHR-1210”, “Camrelizumab” and “camrelizumab + famitinib”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Hepatocellular · Stomach Neoplasms · Triple Negative Breast Neoplasms · Nasopharyngeal Carcinoma, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 475 open or running | phase 3since Mar 28, 2017 | Jun 26, 2015 | none ahead |
| HRYZ Biotech | 21 open or running | phase 1since Dec 27, 2017 | Dec 27, 2017 | none ahead |
| CNBG-Virogin Biotech (Shanghai) | 11 open or running | phase 2since Oct 16, 2023 | Oct 16, 2023 | none ahead |
| CrystalGenomics | 11 open or running | phase 2since Mar 30, 2023 | Mar 30, 2023 | none ahead |
| GrandPharma (China) | 11 open or running | phase 2since Aug 13, 2025 | Aug 13, 2025 | Dec 30, 2027phase 2 · NCT07334483 |
| Guangzhou Virotech Pharmaceutical | 11 open or running | phase 3since May 8, 2026 | May 8, 2026 | Dec 31, 2028phase 3 · NCT07589244 |
| HUTCHMED | 11 open or running | phase 3since Mar 26, 2024 | Mar 26, 2024 | May 31, 2028phase 3 · NCT06361888 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 39 studies since Jun 26, 2015.
- Nov 5, 20202 phase 3 studiesJiangsu HengRui Medicine · NCT04619433, NCT04639180
- Dec 7, 2020Phase 2 study in RecurrenceJiangsu HengRui Medicine · NCT04680988 · 194 enrolled · China
- May 26, 2021Phase 3 study in Uterine Cervical NeoplasmsJiangsu HengRui Medicine · NCT04906993 · 443 enrolled · China
- Jul 15, 2021Phase 3 study in Advanced Hepatocellular Carcinoma (HCC)Jiangsu HengRui Medicine · NCT04985136 · 1 enrolled · China
- Sep 1, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungJiangsu HengRui Medicine · NCT05042375 · 450 planned · China
- Oct 22, 2021Phase 3 study in Advanced NSCLCJiangsu HengRui Medicine · NCT05106335 · 1 enrolled · China
- Jan 28, 2022Phase 2 study in Advanced Solid TumorsJiangsu HengRui Medicine · NCT05214976 · 64 enrolled · China
- Apr 2, 2022Phase 3 study in Carcinoma, HepatocellularJiangsu HengRui Medicine · NCT05320692 · 423 enrolled · China
- Mar 13, 2023Phase 1 study in Advanced TumorsJiangsu HengRui Medicine · NCT05799183 · 12 enrolled · China
- Mar 30, 2023CrystalGenomics's first study: phase 2 study in Non Squamous Non Small Cell Lung CancerNew to CrystalGenomicsCrystalGenomics · NCT05841472 · 60 planned · Korea, Republic of
- Oct 16, 2023CNBG-Virogin Biotech (Shanghai)'s first study: phase 2 study in Carcinoma, HepatocellularNew to CNBG-Virogin Biotech (Shanghai)CNBG-Virogin Biotech (Shanghai) · NCT06124001 · 36 planned
- Mar 26, 2024HUTCHMED's first study: phase 3 study in Pancreatic NeoplasmsNew to HUTCHMEDHUTCHMED · NCT06361888 · 502 planned · China
- Aug 13, 2025GrandPharma (China)'s first study: phase 2 study in HCCNew to GrandPharma (China)GrandPharma (China) · NCT07334483 · 120 planned · China
- May 8, 2026Guangzhou Virotech Pharmaceutical's first study: phase 3 study in HCCNew to Guangzhou Virotech PharmaceuticalGuangzhou Virotech Pharmaceutical · NCT07589244 · 66 planned · China
Ahead
- Dec 30, 2027Primary completion: phase 2 study in HCCGrandPharma (China) · NCT07334483
- May 31, 2028Primary completion: phase 3 study in Pancreatic NeoplasmsHUTCHMED · NCT06361888
- Dec 31, 2028Primary completion: phase 3 study in HCCGuangzhou Virotech Pharmaceutical · NCT07589244
TargetBeta
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 54 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07589244HCC · China | 3 | Recruiting | Guangzhou Virotech Pharmaceutical | Dec 31, 2028 | 66 |
| NCT07334483HCC · China | 2 | Recruiting | GrandPharma (China) | Dec 30, 2027 | 120 |
| NCT06361888Pancreatic Neoplasms · China | 3 | Recruiting | HUTCHMED | May 31, 2028 | 502 |
| NCT06124001Carcinoma, Hepatocellular | 2 | Not yet recruiting | CNBG-Virogin Biotech (Shanghai) | Dec 30, 2025 | 36 |
| NCT05841472Non Squamous Non Small Cell Lung Cancer · Korea, Republic of | 2 | Recruiting | CrystalGenomics | Aug 2026 | 60 |
| NCT05799183Advanced Tumors · China | 1 | Terminated | Jiangsu HengRui Medicine | Oct 12, 2023 | 12 |
| NCT05320692Carcinoma, Hepatocellular · China | 3 | Active, not recruiting | Jiangsu HengRui Medicine | Jul 30, 2026 | 423 |
| NCT05214976Advanced Solid Tumors · China | 2 | UNKNOWN | Jiangsu HengRui Medicine | Jan 31, 2023 | 64 |
| NCT05106335Advanced NSCLC · China | 3 | Terminated | Jiangsu HengRui Medicine | May 11, 2022 | 1 |
| NCT05042375Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Jiangsu HengRui Medicine | Dec 31, 2023 | 450 |
| NCT04985136Advanced Hepatocellular Carcinoma (HCC) · China | 3 | Terminated | Jiangsu HengRui Medicine | Dec 29, 2021 | 1 |
| NCT04906993Uterine Cervical Neoplasms · China | 3 | Active, not recruiting | Jiangsu HengRui Medicine | Jun 10, 2025 | 443 |
| NCT04680988Recurrence · China | 2 | Completed | Jiangsu HengRui Medicine | Jul 7, 2025 | 194 |
| NCT04639180Carcinoma, Hepatocellular · China | 3 | Active, not recruiting | Jiangsu HengRui Medicine | Jul 31, 2026 | 687 |
| NCT04619433Non-squamous Non-small-cell Lung Cancer · China | 3 | Terminated | Jiangsu HengRui Medicine | Aug 16, 2025 | 48 |
| NCT04613674Triple Negative Breast Neoplasms · China | 3 | Completed | Jiangsu HengRui Medicine | Sep 14, 2023 | 441 |
| NCT04426955Esophageal Neoplasms · China | 3 | UNKNOWN | Jiangsu HengRui Medicine | Dec 2022 | 396 |
| NCT04346381Solid Tumor · China | 2 | Completed | Jiangsu HengRui Medicine | Jun 22, 2022 | 233 |
| NCT04342936Classical Hodgkin Lymphoma · China | 3 | UNKNOWN | Jiangsu HengRui Medicine | Aug 1, 2023 | 56 |
| NCT04342910Stomach Neoplasms · China | 3 | Recruiting | Jiangsu HengRui Medicine | Apr 1, 2026 | 550 |
| NCT04335006Breast Neoplasms · China | 3 | Terminated | Jiangsu HengRui Medicine | Apr 14, 2023 | 80 |
| NCT04203485PD-L1 Positive Non-small Cell Lung Cancer | 3 | UNKNOWN | Jiangsu HengRui Medicine | Mar 31, 2022 | 762 |
| NCT04074564Sarcoma · China | Early 1 | Recruiting | HRYZ Biotech | Aug 7, 2024 | 60 |
| NCT03945604Triple Negative Breast Neoplasms · China | 1 | Completed | Jiangsu HengRui Medicine | Feb 9, 2021 | 32 |
| NCT03813784Stomach Neoplasms · China | 3 | Completed | Jiangsu HengRui Medicine | Jun 7, 2023 | 885 |
| NCT03777124Carcinoma, Non-Small-Cell Lung · China | 2 | Terminated | Jiangsu HengRui Medicine | Jun 29, 2023 | 25 |
| NCT03764293Neoplasm Metastasis · United States, Belgium, China and more | 3 | Completed | Jiangsu HengRui Medicine | Feb 8, 2022 | 543 |
| NCT03827837Carcinoma, Renal Cell · China | 2 | UNKNOWN | Jiangsu HengRui Medicine | Dec 2022 | 265 |
| NCT03711279Sarcoma · China | 2 | Terminated | Jiangsu HengRui Medicine | Jun 21, 2021 | 99 |
| NCT03707509Nasopharyngeal Carcinoma · China | 3 | UNKNOWN | Jiangsu HengRui Medicine | Aug 1, 2021 | 263 |
| NCT03691090Advanced Esophageal Cancer · China | 3 | Completed | Jiangsu HengRui Medicine | Oct 30, 2020 | 596 |
| NCT03668496Lung Neoplasms · China | 3 | UNKNOWN | Jiangsu HengRui Medicine | Nov 6, 2020 | 390 |
| NCT03666728Lung Neoplasms · China | 2 | Terminated | Jiangsu HengRui Medicine | Mar 11, 2020 | 5 |
| NCT03645876Colorectal Neoplasms · China | 2 | Terminated | Jiangsu HengRui Medicine | Apr 18, 2019 | 12 |
| NCT03605706Advanced Hepatocellular Carcinoma · China | 3 | UNKNOWN | Jiangsu HengRui Medicine | Feb 2023 | 396 |
| NCT03558191Nasopharyngeal Carcinoma · China | 2 | Completed | Jiangsu HengRui Medicine | Dec 30, 2021 | 156 |
| NCT03491631Neoplasms · China | 1 | UNKNOWN | Jiangsu HengRui Medicine | Jun 2023 | 23 |
| NCT03472365Stomach Neoplasms · China | 2 | Completed | Jiangsu HengRui Medicine | Nov 25, 2020 | 67 |
| NCT03463876Carcinoma, Hepatocellular · China | 2 | Completed | Jiangsu HengRui Medicine | Mar 10, 2021 | 190 |
| NCT03417895Small Cell Lung Carcinoma · China | 2 | Completed | Jiangsu HengRui Medicine | Aug 4, 2021 | 59 |
| NCT03393416Advanced Gastric Cancer · China | 1 | UNKNOWN | HRYZ Biotech | Jul 2020 | 28 |
| NCT03363555Lymphoma, Extranodal NK-T-Cell · China | 2 | UNKNOWN | Jiangsu HengRui Medicine | Jun 30, 2019 | 97 |
| NCT03182673Solid Tumor · China | 1 | Terminated | Jiangsu HengRui Medicine | Jun 12, 2019 | 31 |
| NCT03155425Hodgkin Disease · China | 2 | Completed | Jiangsu HengRui Medicine | Aug 31, 2020 | 75 |
| NCT03134872Lung Neoplasms · China | 3 | Completed | Jiangsu HengRui Medicine | Jul 27, 2019 | 419 |
| NCT03121716Nasopharyngeal Carcinoma · China | 1 | Completed | Jiangsu HengRui Medicine | Jul 28, 2020 | 23 |
| NCT03099382Esophageal Neoplasms · China | 3 | Completed | Jiangsu HengRui Medicine | May 6, 2019 | 457 |
| NCT03085069Lung Neoplasms · China | 2 | UNKNOWN | Jiangsu HengRui Medicine | Aug 20, 2020 | 146 |
| NCT03083041Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Jiangsu HengRui Medicine | Apr 22, 2022 | 210 |
| NCT02989922Hepatocellular Carcinoma Non-Resectable · China | 2 | Completed | Jiangsu HengRui Medicine | Mar 3, 2020 | 220 |
| NCT02742935Breast Neoplasms · China | 1 | Completed | Jiangsu HengRui Medicine | May 6, 2019 | 99 |
| NCT02738489Advanced Melanoma · China | 1 | Completed | Jiangsu HengRui Medicine | Jan 8, 2020 | 36 |
| NCT02721589Advanced Solid Tumors · China | 1 | Completed | Jiangsu HengRui Medicine | Nov 17, 2019 | 126 |
| NCT02492789Hematologic Neoplasms · Australia | 1 | Completed | Jiangsu HengRui Medicine | Mar 1, 2019 | 49 |
How it is read
Names in the registry
- “SHR-1210”, 25 entries
- “Camrelizumab”, 6 entries
- “camrelizumab”, 4 entries
- “camrelizumab + famitinib”, 2 entries
- “VRT106 in combination with camrelizumab and apatinib”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 8 studies
- Carcinoma, Hepatocellular, 7 studies
- Stomach Neoplasms, 4 studies
- Triple Negative Breast Neoplasms, 3 studies
- Nasopharyngeal Carcinoma, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.